<DOC>
	<DOCNO>NCT01517776</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy combine treatment cilengitide metronomic oral temozolomide measure 6 month overall survival ( OS ) diagnosis relapse tumour progression child adolescent relapse refractory high-grade malignant glioma diffuse intrinsic pontine glioma . Secondary objective include : 1 . To evaluate safety toxicity study treatment common toxicity criterion ( CTC ; version 4.0 ) . 2 . To assess - response rate 6 month ( continuous complete response = CCR , complete response = CR , partial response = PR , stable disease = SD , progressive disease = PD ) - progression-free survival ( PFS ) 6 month , - response rate , OS , PFS 12 month relapse diagnosis diagnosis tumor progression . Response present include histopathological variant . 3 . To assess pharmacokinetics cilengitide administer part study treatment . Indication study population trial : Treatment relapse refractory high grade glioma diffuse intrinsic pontine glioma paediatric patient ≥ 3 year &lt; 18 year age . Patients include study receive - Cilengitide 1800 mg/m² i.v . twice weekly - Temozolomide 75 mg/m²/d p.o . 6 week , follow 1 week rest mandatory platelet-count dependent dose adaptation rule : mandatory blood count twice weekely : Platelets ≥ 100 000/µl ( ≥ 100 Gpt/l ) : 75 mg/m² , platelet ≥ 50 000 - &lt; 100 000/µl ( ≥ 50 - &lt; 100 Gpt/l ) : 50 mg/m² , platelet &lt; 50 000/µl ( &lt; 50 Gpt/l ) : stop temozolomide platelet recovery ≥ 100 000/µl ( ≥100 Gpt/l ) - Study treatment individual patient schedule 1 year unless tumor progression excessive toxicity occur . However , study treatment may extend beyond 1 year upon individual decision .</brief_summary>
	<brief_title>Cilengitide Metronomic Temozolomide Relapsed Refractory High Grade Gliomas Diffuse Intrinsic Pontine Gliomas Children Adolescents</brief_title>
	<detailed_description>Indication : Treatment relapse refractory high grade glioma diffuse intrinsic pontine glioma paediatric patient ≥ 3 year &lt; 18 year age . Background rationale : Relapsed refractory high-grade glioma diffuse intrinsic pontine glioma ( follow address high grade glioma = HGG ) child adolescent represent bad prognosis group recommend standard salvage therapy currently available . The combination cilengitide metronomic temozolomide investigate present trial new treatment strategy patient . Metronomic temozolomide show act via inhibition tumour angiogenesis cytotoxic agent . Cilengitide might act via tumour angiogenesis also inhibit tumour cell migration . For drug , safe dos low toxicity define phase I trials paediatric patient recurrent refractory brain tumour ( Cilengitide : 1800 mg/m² twice weekly ; metronomic Temozolomide : 75-80 mg/m²/d 6 week schedule follow one week rest ) In phase II trial adult patient relapse glioblastoma cilengitide single agent show trend towards higher efficacy 2000 mg twice weekly compare 500 mg twice weekly . Furthermore , phase II trial newly diagnose adult glioblastoma patient , sign clinical activity cilengitide combination radiotherapy conventional temozolomide see methylated MGMT gene promoter subgroup . Based finding , large randomize phase III trial investigate cilengitide combination standard therapy ( temozolomide radiation ) subgroup start recently . Metronomic temozolomide also show still effective glioma patient suffer relapse temozolomide standard therapy . Interestingly , mode action appear widely independent MGMT status , probably due MGMT depletion continuous treatment . In conclusion , drug sign clinical activity show relapsed glioblastoma patient , even failure temozolomide standard therapy . Study design : Prospective , non-randomized phase II trial . Study population : Patients 3 year &lt; 18 year age high grade glioma diffuse intrinsic pontine glioma relapse refractory standard therapy recruit approved trial site Sample size : It plan include 33 patient . Therapy : Patients include study receive - Cilengitide 1800 mg/m² i.v . twice weekly - Temozolomide 75 mg/m²/d p.o . 6 week , follow 1 week rest mandatory platelet-count dependent dose adaptation rule : mandatory blood count twice weekely : Platelets ≥ 100 000/µl ( ≥ 100 Gpt/l ) : 75 mg/m² , platelet ≥ 50 000 - &lt; 100 000/µl ( ≥ 50 - &lt; 100 Gpt/l ) : 50 mg/m² , platelet &lt; 50 000/µl ( &lt; 50 Gpt/l ) : stop temozolomide platelet recovery ≥ 100 000/µl ( ≥100 Gpt/l ) - Study treatment individual patient schedule 1 year unless tumor progression excessive toxicity occur . However , study treatment may extend beyond 1 year upon individual decision . Biometry : Statistical analysis sample size calculation : The feasibility efficacy HIT-HGG-CilMetro therapy assess single stage analysis . Sample size calculation base 6 month overall survival rate . This survival rate find 44 % historical study population HIT-GBM data base . An overall survival rate 59 % present study consider clinical relevance . Based one side one sample χ2-test significance level α=5 % sample size 33 patient plan . This sample size implies power 50 % . Schedule : The study schedule start January 1 , 2012 . The recruitment period trial last 24 month December 31 , 2013 . Individual follow-up least 1 year study entry require protocol . The study finish 30 day completion study treatment last patient enrol , i.e . expect end trial January 31 , 2015 . Long-term follow-up strongly recommend organised via HIT-HGG Study Office . If start study delay , give date change accordingly . Financial support : Merck KGaA , Darmstadt , Germany , provide grant conduct trial , supply Cilengitide free charge agree perform laboratory assessment pharmacokinetics .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Diagnosis highgrade malignant glioma confirm central neuropathological review ( last MRI diagnosis old 4 week ) include glioblastoma multiforme ( WHO IV ) , anaplastic astrocytoma ( WHO III ) , anaplastic oligodendroglioma ( WHO III ) , anaplastic oligoastrocytoma ( WHO III ) , anaplastic pilocytic astrocytoma ( WHO III ) , anaplastic ganglioglioma ( WHO III ) , anaplastic pleomorphic xanthoastrocytoma ( analogous WHO III ) , giant cell glioblastoma ( WHO IV ) , gliosarcoma ( WHO IV ) diagnosis diffuse intrinsic pontine glioma confirm central neuroradiological review refractory standard treatment , relapse progressive firstline therapy . 2 . Patient age 3 year old 18 year time relapse diagnosis 3 . Written informed consent patient ( mandatory 15 year age ) parent ( mandatory till 18 year age ) . 1 . Known hypersensitivity contraindication study drug 2 . Other ( simultaneous ) malignancies 3 . Pregnancy / lactation 4 . Patients sexually active refusing use effective contraception ( oral contraception , intrauterine device , barrier method contraception conjunction spermicidal jelly surgical sterile ) 5 . Current recent ( within 30 day prior start trial treatment ) treatment another investigational drug participation another investigational trial 6 . Severe concomitant disease ( e.g . immune deficiency syndrome ) HIV infection 7 . Severe psychological disease neurological damage without possibility communicate 8 . Clinical sign intracranial pressure 9 . Intracerebral hemorrhage history intracerebral hemorrhage 10 . Requirements laboratory test result older 2 week patient´s inclusion : Platelets &lt; 100 000/µl ( &lt; 100 Gpt/l ) PT , INR PTT normal range Absulute neutrophil count ≤ 1 500/µl ( &lt; 1,5 Gpt/l ) Hemoglobin &lt; 10g/dl ( &lt; 6,4 mmol/L ) Serum creatinine ≥ 1,5 x upper limit normal range creatinine clearance rate ≤ 60 ml/min/m2 ( correct body surface area ) Total bilirubin ≥ 1,5 x upper limit normal range SGOT ( ASAT ) SGPT ( ALAT ) ≥ 2,5 x upper limit normal range Alkaline phosphatase ≥ 2,5 x upper limit normal range 11 . Hereditary Intrinsic Platelet Disorders 12 . Ongoing irradiation chemotherapy ( within last 4 week ) 13 . Estimated life expectancy le 2 month</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>High grade glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Diffuse intrinsic pontine glioma</keyword>
	<keyword>Relapse</keyword>
	<keyword>refractory tumour disease</keyword>
	<keyword>Relapsed refractory high grade glioma diffuse intrinsic pontine glioma</keyword>
</DOC>